Cargando…
The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life
A drug’s biological half-life is defined as the time required for the human body to metabolize or eliminate 50% of the initial drug dosage. Correctly measuring the half-life of a given drug is helpful for the safe and accurate usage of the drug. In this study, we investigated which gene ontology (GO...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079577/ https://www.ncbi.nlm.nih.gov/pubmed/27780226 http://dx.doi.org/10.1371/journal.pone.0165496 |
_version_ | 1782462568118353920 |
---|---|
author | Zhang, Yu-Hang Chu, Chen Wang, Shaopeng Chen, Lei Lu, Jing Kong, XiangYin Huang, Tao Li, HaiPeng Cai, Yu-Dong |
author_facet | Zhang, Yu-Hang Chu, Chen Wang, Shaopeng Chen, Lei Lu, Jing Kong, XiangYin Huang, Tao Li, HaiPeng Cai, Yu-Dong |
author_sort | Zhang, Yu-Hang |
collection | PubMed |
description | A drug’s biological half-life is defined as the time required for the human body to metabolize or eliminate 50% of the initial drug dosage. Correctly measuring the half-life of a given drug is helpful for the safe and accurate usage of the drug. In this study, we investigated which gene ontology (GO) terms and biological pathways were highly related to the determination of drug half-life. The investigated drugs, with known half-lives, were analyzed based on their enrichment scores for associated GO terms and KEGG pathways. These scores indicate which GO terms or KEGG pathways the drug targets. The feature selection method, minimum redundancy maximum relevance, was used to analyze these GO terms and KEGG pathways and to identify important GO terms and pathways, such as sodium-independent organic anion transmembrane transporter activity (GO:0015347), monoamine transmembrane transporter activity (GO:0008504), negative regulation of synaptic transmission (GO:0050805), neuroactive ligand-receptor interaction (hsa04080), serotonergic synapse (hsa04726), and linoleic acid metabolism (hsa00591), among others. This analysis confirmed our results and may show evidence for a new method in studying drug half-lives and building effective computational methods for the prediction of drug half-lives. |
format | Online Article Text |
id | pubmed-5079577 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-50795772016-11-04 The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life Zhang, Yu-Hang Chu, Chen Wang, Shaopeng Chen, Lei Lu, Jing Kong, XiangYin Huang, Tao Li, HaiPeng Cai, Yu-Dong PLoS One Research Article A drug’s biological half-life is defined as the time required for the human body to metabolize or eliminate 50% of the initial drug dosage. Correctly measuring the half-life of a given drug is helpful for the safe and accurate usage of the drug. In this study, we investigated which gene ontology (GO) terms and biological pathways were highly related to the determination of drug half-life. The investigated drugs, with known half-lives, were analyzed based on their enrichment scores for associated GO terms and KEGG pathways. These scores indicate which GO terms or KEGG pathways the drug targets. The feature selection method, minimum redundancy maximum relevance, was used to analyze these GO terms and KEGG pathways and to identify important GO terms and pathways, such as sodium-independent organic anion transmembrane transporter activity (GO:0015347), monoamine transmembrane transporter activity (GO:0008504), negative regulation of synaptic transmission (GO:0050805), neuroactive ligand-receptor interaction (hsa04080), serotonergic synapse (hsa04726), and linoleic acid metabolism (hsa00591), among others. This analysis confirmed our results and may show evidence for a new method in studying drug half-lives and building effective computational methods for the prediction of drug half-lives. Public Library of Science 2016-10-25 /pmc/articles/PMC5079577/ /pubmed/27780226 http://dx.doi.org/10.1371/journal.pone.0165496 Text en © 2016 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Zhang, Yu-Hang Chu, Chen Wang, Shaopeng Chen, Lei Lu, Jing Kong, XiangYin Huang, Tao Li, HaiPeng Cai, Yu-Dong The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life |
title | The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life |
title_full | The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life |
title_fullStr | The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life |
title_full_unstemmed | The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life |
title_short | The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life |
title_sort | use of gene ontology term and kegg pathway enrichment for analysis of drug half-life |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079577/ https://www.ncbi.nlm.nih.gov/pubmed/27780226 http://dx.doi.org/10.1371/journal.pone.0165496 |
work_keys_str_mv | AT zhangyuhang theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT chuchen theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT wangshaopeng theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT chenlei theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT lujing theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT kongxiangyin theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT huangtao theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT lihaipeng theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT caiyudong theuseofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT zhangyuhang useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT chuchen useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT wangshaopeng useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT chenlei useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT lujing useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT kongxiangyin useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT huangtao useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT lihaipeng useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife AT caiyudong useofgeneontologytermandkeggpathwayenrichmentforanalysisofdrughalflife |